Preserved SARS-CoV-2 Vaccine Cell-Mediated Immunogenicity in Inflammatory Bowel Disease Patients on Immune-Modulating Therapies
Description
Immune-modulating medications for inflammatory bowel diseases (IBD) have been associated with suboptimal vaccine responses. There is conflicting data with SARS-CoV-2 vaccination. We therefore assessed SARS-CoV-2 vaccine immunogenicity at 2 weeks post
